-
PPACK Dihydrochloride: Thrombin Assay Workflows
2026-09-03
PPACK Dihydrochloride enables high-affinity, irreversible thrombin suppression in platelet, coagulation, and receptor-signaling experiments. This guide shows how to build thrombin-controlled workflows, separate purinergic effects from thrombin signaling, and troubleshoot incomplete inhibition or assay drift.
-
BMAL1 Phase Separation Builds Circadian Transcription Hubs
2026-09-03
Gao et al. identify BMAL1 as a phosphorylation-tunable phase-separating protein that organizes CLOCK, p300, MED1, and E-box DNA into dynamic nuclear transcriptional hubs. Genetic deletion and rescue experiments connect the N-terminal intrinsically disordered region to rhythmic transcription in cells and locomotor rhythms in mice, providing a spatial explanation for delayed circadian transcriptional output.
-
KR-12 and LL-37: Antibiofilm Study Insights
2026-09-02
The 2017 Frontiers in Microbiology study showed that LL-37 and its truncated mimetics KE-18 and KR-12 can separate planktonic killing from biofilm prevention. Its central contribution is a comparative, assay-based demonstration that peptide optimization for minimum inhibitory concentration does not necessarily predict activity against established or developing biofilms.
-
Tubastatin A: Designing Better Cell-Death Assays
2026-09-02
Tubastatin A is a selective HDAC6 inhibitor with emerging value in cardiac ischemia–reperfusion research. This guide translates porcine post-resuscitation findings into rigorous assay design, endpoint selection, and causal interpretation.
-
Glutamine Metabolism in Hepatic Stellate Cells
2026-09-01
The reference study identifies a SIRT4–GDH metabolic axis that links glutamine catabolism to hepatic stellate cell activation and liver fibrosis. Its combination of pharmacological GDH inhibition, SIRT4 modulation, cell-based assays, and animal models provides a mechanistic framework for evaluating metabolism-directed antifibrotic strategies.
-
VX-745: A Precision Tool for p38α MAPK Research
2026-09-01
VX-745 is a potent, selective p38α MAPK inhibitor for dissecting inflammatory, oncogenic, and aging-associated signaling. This guide goes beyond target inhibition to show how assay architecture can distinguish catalytic blockade from changes in p38α phosphorylation-state dynamics.
-
Antimycin A4: A Two-Axis Assay Strategy
2026-08-31
Antimycin A4 is an ATP-citrate lyase inhibitor and mitochondrial respiratory chain probe with unusual dual-pathway value. This guide develops an orthogonal assay strategy that separates lipid-biosynthesis effects from respiratory-chain stress while addressing chemical identity, controls, and translational limits.
-
GANT61: Practical GLI Inhibition Workflows
2026-08-31
GANT61 is a selective GLI inhibitor for connecting Hedgehog-pathway activity with tumor-cell phenotypes and immune-evasive behavior. This workflow-focused guide covers solvent handling, dose-response design, neuroblastoma models, tumor–immune assays, and troubleshooting for reproducible cancer research.
-
Artesunate: Mapping Cancer Drug Responses
2026-08-30
Artesunate research is more informative when potency is separated from proliferation arrest and cell death. This guide combines Artesunate biology with a time-resolved assay strategy for small cell lung carcinoma research and related cancer models.
-
ECL Chemiluminescent Substrate Detection Kit Guide
2026-08-29
Learn how to apply hypersensitive HRP-based detection to low-abundance Western blot targets, including pathway proteins relevant to colorectal cancer research. This workflow emphasizes membrane selection, exposure strategy, background control, and practical troubleshooting for reliable signal recovery.
-
Streptavidin Magnetic Beads for Assay Workflows
2026-08-28
Learn how Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) can support reproducible capture, cleanup, and enrichment steps in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects assay design, protocol optimization, data interpretation, and practical vendor selection.
-
Cisplatin Workflows for Resistance Research
2026-08-28
Build reproducible CDDP experiments around fresh preparation, matched vehicle controls, and orthogonal measures of DNA damage, ROS, and apoptosis. Extend the benchmark into chemotherapy resistance studies and responsive co-delivery systems without confusing formulation effects with cisplatin biology.
-
Chloroquine Pharmacogenomics: Risk, Evidence & Outlook
2026-08-27
The 2023 review by Biswas and Sukasem consolidates pharmacogenomic evidence for chloroquine and hydroxychloroquine, focusing on CYP2C8, CYP3A5, CYP3A4/5, and CYP2D6 variation. Its practical contribution is a risk-phenotype framework showing how ultra-rapid and poor metabolizer profiles may contribute to therapeutic failure or toxicity across patient populations.
-
Methylprednisolone in Bone-Loss Research
2026-08-27
Use Methylprednisolone as a controlled glucocorticoid challenge to connect inflammatory signaling with osteoclast-driven bone loss. This workflow combines cell-based cytokine assays, a literature-grounded rat GIONFH model, and practical formulation controls for more reproducible translational studies.
-
LY364947: TGF-β Type I Receptor Kinase Inhibitor
2026-08-26
LY364947 provides a pathway-proximal way to test how TGF-β drives Smad2 activation, epithelial-mesenchymal transition, fibrosis-related phenotypes, and retinal injury responses. This practical guide connects receptor inhibition with the CDK4/6–BET findings in pancreatic cancer and outlines assay-ready workflows, controls, and troubleshooting strategies.